lobbying_activities: 2429315
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2429315 | 0dad3a65-2c9c-4a1d-a62b-20b53fc1ccf8 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2020 | first_quarter | CPT | Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019. Issues related to H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2020-04-16T16:34:00.480000-04:00 |